Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers

Abstract

The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes). Other statistically significant associations were found in subgroups defined by smoking habits (never or ex-smokers), environmental tobacco smoke or gender, with no obvious pattern. When gene variants were organized according to the three main pathways, the emerging picture was of a strong involvement of combined phase I enzymes in leukemia, with an OR of 5 (1.63-15.4) for those having three or more variant alleles. The association was considerably stronger for leukemias arising before the age of 55.

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

“…After further retrieved, 12 articles were excluded because of the following reasons: three were for review or meta-analysis articles (Gonzalez, 1997;Chao et al, 2006;Ersoy Tunali et al, 2011); one did not focus on the NQO1 rs1800566 polymorphism but on NQO2 (exon 3, T14055C) polymorphism (Wen et al, 2009); two were for the correlation between the NQO1 rs1800566 polymorphism and NQO1 activity (Basu et al, 2004;Jamieson et al, 2007); two were for the correlation between the NQO1 rs1800566 polymorphism and p53 mutations (Martone et al, 2000;Ryk et al, 2006); one was for the correlation between the NQO1 rs1800566 polymorphism and clinical course of bladder cancer (Sanyal et al, 2007); Three studies did not report gene frequencies (Vineis et al, 2007;Dhaini et al, 2012;Ersoy Tunali et al, 2012). Therefore, 12 studies (Schulz et al, 1997;Choi et al, 2003;Park et al, 2003;Hung et al, 2004;Moore et al, 2004;Sanyal et al, 2004;Broberg et al, 2005;Terry et al, 2005;Figueroa et al, 2008;Wang et al, 2008;Paonessa et al, 2009;Pandith et al, 2011) were included in our meta-analysis.…”

Allele and Genotype Frequencies of the Polymorphic Methylenetetrahydrofolate Reductase and Lung Cancer in ther Jordanian Population: a Case Control Study

“…Generally speaking, the number of studies that evaluated the relationship between MTHFR genetic polymorphism and LC risk is few and moreover their findings have been conflicting where some yielded an increased risk (Siemianowicz et al, 2003;Shen et al, 2005;Hung et al, 2007;Vineis et al, 2007;Arslan et al, 2011), a decreased risk (Jeng et al, 2003;Shi et al, 2003;Suzuki et al, 2007;Liu et al, 2009;Cui et al, 2011) or no association (Shen et al, 2001;Heijmans et al, 2003;Liu et al, 2008;Truong et al, 2010).…”

Secondhand Tobacco Smoke

“…Using case-control data for never and former smokers nested within the EPIC study Vineis et al (2007b) examined susceptibility in genes involved in oxidative stress (such as NQO1, MPO, COMT, MnSOD), in phase I (such as CYP1A1 and CYP1B1) and phase II (such as GSTM1, and GSTT1) metabolizing genes, and in methylenetetrahydrofolate (MTHFR). GSTM1 deletion was strongly associated with risk for urinary bladder cancer in never smokers (OR, 1.75; 95%CI: 0.89-3.43), and a similar association was noted for former smokers and for men.…”